Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC combined with apatinib and adebrelimab for high-risk BCLC stage C hepatocellular carcinoma
ChiCTR2600131403Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and adebrelimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall survival. Started May 2025; status: recruiting.
02
Drugs
Rivoceranibadebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600131403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131403.